Goldman Sachs raised the firm’s price target on uniQure (QURE) to $10 from $9 and keeps a Neutral rating on the shares.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QURE:
- uniQure call volume above normal and directionally bullish
- Hemmati eyed for top vaccine and gene therapy regulator role, Bloomberg says
- uniQure put volume heavy and directionally bearish
- Passage Bio initiated with an Outperform at Oppenheimer
- U.S. Chess Champion Dips Below the S&P as Tech Stock Picks Falter